IP Library Patent Application 10585440
Patent Application
App. No. 10/585,440

Vectors for Recombinant Protein Expression in E. Coli

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/585,440
Abstract

The present invention relates to methods of providing a protein product to a customer. In particular, the invention relates methods of using protein expression vectors to produce proteins to be provided to a client. The invention also provides vectors for the cloning and expression of proteins, including reagent proteins and therapeutic proteins.

Claims (58)

1 . A method of providing a therapeutic protein to a customer, said method comprising cloning a nucleic acid encoding said protein into a pCWinl expression vector as set forth in SEQ ID NO:1, expressing said protein therefrom, and providing said protein to said customer.

2 . A method of providing a therapeutic protein to a customer, said method comprising cloning a nucleic acid encoding said protein into a pCWin 2 expression vector as set forth in SEQ ID NO:2, expressing said protein therefrom, and providing said protein to said customer.

3 . A method of providing a therapeutic protein to a customer, said method comprising cloning a nucleic acid encoding said protein into a nucleic acid vector selected from the group consisting of:

a) a pCWin2/MBP expression vector as set forth in SEQ ID NO:3;

b) a pCWin2-MBP-SBD (pMS 39 ) expression vector as set forth in SEQ ID NO:10; and

c) a pCWin2-MBP-MCS-SBD (pMXSp 39 ) expression vector as set forth in SEQ ID NO:11;

expressing said protein therefrom, and providing said protein to said customer.

4 . The method of claim 3 , wherein said nucleic acid vector comprises a protease cleavage site coding sequence at a location selected from the group consisting of:

a) between the MBP coding sequence and the therapeutic protein coding sequence; and

b) immediately prior to the start of the C-terminus of the MBP coding sequence.

5 . The method of claim 2 or 3 , wherein said protein is selected from the group consisting of erythropoietin, human growth hormone, granulocyte colony stimulating factor, interferons alpha, -beta, and -gamma, Factor IX, follicle stimulating hormone, interleukin-2, erythropoietin, anti-TNF-alpha, and a lysosomal hydrolase.

6 . The method of claim 5 , wherein said lysosomal hydrolase is selected from the group consisting of beta-glucosidase, alpha-galactosidase-A, beta-hexosaminidase, beta-galactosidase, alpha-galactosidase, alpha-mannosidase, beta-mannosidase, alpha-L-fucosidase, beta-glucuronidase, alpha-glucosidase, alpha-N-acetylgalactosaminidase, and acid phosphatase.

7 . A method of providing a protein to a customer, said method comprising cloning a nucleic acid encoding said protein into a pCWin1 expression vector as set forth in SEQ ID NO:1, expressing said protein therefrom, and providing said protein to said customer.

8 . A method of providing a protein to a customer, said method comprising cloning a nucleic acid encoding said protein into a pCWin2 expression vector as set forth in SEQ ID NO:2, expressing said protein therefrom, and providing said protein to said customer.

9 . A method of providing a protein to a customer, said method comprising cloning a nucleic acid encoding said protein into a nucleic acid vector selected from the group consisting of:

a) a pCWin2/MBP expression vector as set forth in SEQ ID NO:3;

b) a pCWin2-MBP-SBD (pMS 39 ) expression vector as set forth in SEQ ID NO:10; and

c) a pCWin2-MBP-MCS-SBD (pMXS 39 ) expression vector as set forth in SEQ ID NO:11;

expressing said protein therefrom, and providing said protein to said customer.

10 . The method of claim 7 , 8 or 9 , wherein said protein is selected from the group consisting of a glycosyltransferase and a sugar nucleotide-generating enzyme.

11 . A method of providing a protein to a customer, said method comprising providing a pCWin1 vector as set forth in SEQ ID NO:1 to a protein production facility, wherein a nucleic acid encoding said protein is cloned into said expression vector and said protein is expressed therefrom in said protein production facility, and providing said protein to said customer.

12 . A method of providing a protein to a customer, said method comprising providing a pCWin2 vector as set forth in SEQ ID NO:2 to a protein production facility, wherein a nucleic acid encoding said protein is cloned into said expression vector and said protein is expressed therefrom in said protein production facility, and providing said protein to said customer.

13 . A method of providing a protein to a customer, said method comprising providing a nucleic acid vector selected from the group consisting of:

a) a pCWin2/MBP expression vector as set forth in SEQ ID NO:3;

b) a pCWin2-MBP-SBD (pMS 39 ) expression vector as set forth in SEQ ID NO:10; and

c) a pCWin2-MBP-MCS-SBD (pMXS 39 ) expression vector as set forth in SEQ ID NO:11;

to a protein production facility, wherein a nucleic acid encoding said protein is cloned into said expression vector and said protein is expressed therefrom in said protein production facility, and providing said protein to said customer.

14 . The method of claim 2 , 3 , 4 , 7 , 8 or 9 , wherein said method further comprises prior to providing said protein to said customer, at least one glycosyl moiety is added to said protein.

15 . The method of claim 14 , wherein said glycosyl moiety is added to said protein in vitro.

16 . A method of providing a protein to a customer, said method comprising cloning a nucleic acid encoding said protein into-nucleic acid vector selected from the group consisting of:

a) a pCWin1 vector as set forth in SEQ ID NO:1;

b) a pCWin2 vector as set forth in SEQ ID NO:2;

c) a pCWin2/MBP vector as set forth in SEQ ID NO:3;

d) a pCWin2-MBP-SBD (pMS 39 ) vector as set forth in SEQ ID NO:10; and

e) a pCWin2-MBP-MCS-SBD (pMXS 39 ) vector as set forth in SEQ ID NO:11;

further wherein said method comprises inserting said vector into a bacterial host cell, expressing said protein in said host cell, and providing said protein to said customer.

17 . The method of claim 16 , wherein said method further comprises prior to providing said protein to said customer, at least one glycosyl moiety is added to said protein.

18 . The method of claim 16 , wherein said glycosyl moiety is added to said protein in vitro.

19 . The method of claim 16 , wherein said expression vector further comprises an affinity tag coding sequence.

20 . An isolated pcWIN1 expression vector comprising the sequence set forth in SEQ ID NO:1.

21 . An isolated pcWIN1 expression vector consisting of the sequence set forth in SEQ ID NO:1.

22 . An isolated pcWIN2 expression vector comprising the sequence set forth in SEQ ID NO:2.

23 . An isolated pcWIN2 expression vector consisting of the sequence set forth in SEQ ID NO:2.

24 . An isolated pcWIN2/MBP expression vector comprising the sequence set forth in SEQ ID NO:3.

25 . An isolated pcWIN2/MBP expression vector consisting of the sequence set forth in SEQ ID NO:3.

26 . The pcWIN280P expression vector of claim 24 , wherein the pCWIN2/MBP vector comprises a protease cleavage site coding sequence adjacent to the MBP coding sequence.

27 . An isolated pCWin2-MBP-SBD (pMS 39 ) vector comprising the sequence set forth in SEQ ID NO:10.

28 . An isolated pCWin2-MBP-SBD (pMS 39 ) vector consisting of the sequence set forth in SEQ ID NO:10.

29 . An isolated pCWin2-MBP-MCS-SBD (pMXS 39 ) vector comprising the sequence set forth in SEQ ID NO:11.

30 . An isolated pCWin2-MBP-MCS-SBD (pMXS 39 ) vector consisting of the sequence set forth in SEQ ID NO:11.

31 . The pCWin2-MBP-SBD (pMS 39 ) expression vector of claim 27 , wherein the pCWin2-MBP-SBD (pMS 39 ) vector comprises a protease cleavage site coding sequence immediately prior to the start of the C-terminus of the MBP coding sequence.

32 . A method of expressing a protein, said method comprising cloning a nucleic acid encoding said protein into a pCWin1 expression vector as set forth in SEQ ID NO:1 and expressing said protein therefrom.

33 . A method of expressing a protein, said method comprising cloning a nucleic acid encoding said protein into a pCWin2 expression vector as set forth in SEQ ID NO:2 and expressing said protein therefrom.

34 . A method of expressing a protein, said method comprising cloning a nucleic acid encoding said protein into a nucleic acid vector selected from the group consisting of:

a) a pCWin2/MBP expression vector as set forth in SEQ ID NO:3;

b) a pCWin2-MBP-SBD (pMS 39 ) expression vector as set forth in SEQ ID NO:10; and c) a pCWin2-MBP-MCS-SBD (pMXS 39 ) expression vector as set forth in SEQ ID NO:11;

and expressing said protein therefrom.

35 . The method of any one of claims 32 - 34 , wherein said protein is expressed in a prokaryotic cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2009
From: NEOSE TECHNOLOGIES, INC.
To: NOVO NORDISK A/S
Reel/Frame 022689/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2007
From: JOHNSON, KARL F.; BEZILA, DAN; NGO, WINNIE; HAKES, DAVID
To: NEOSE TECHNOLOGIES, INC.
Reel/Frame 019264/0249 →